GlassScriptPhysician profile
Robert L Masci
NPI 1730139619
$18,892.49
in general payments reported to CMS, 2019-2025
24 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $200 · 2021: $24.45 · 2022: $225 · 2023: $1,054 · 2024: $709 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15,016.63 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $761.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $670.52 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $532.80 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $414.10 | 2019-2025 | Lifevest |
| Pfizer INC. | $223.84 | 2019-2025 | |
| Novo Nordisk INC | $222.23 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $198.96 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $163.45 | 2019-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| Sanofi-Aventis U.S. LLC | $121.32 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $103.63 | 2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $78.54 | 2023-2025 | Farxiga, Lokelma |
| Esperion Therapeutics, INC. | $68.33 | 2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $64.23 | 2019 | |
| Amarin Pharma, INC. | $44.22 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $38.00 | 2025 | Attruby |
| Medtronic, INC. | $33.90 | 2021-2025 | Symplicity G3 |
| Lexicon Pharmaceuticals, INC. | $31.85 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $27.78 | 2022-2023 | Verquvo |
| United Therapeutics Corporation | $16.80 | 2023 | Tyvaso |
| Heartflow, INC. | $16.55 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Currax Pharmaceuticals LLC | $14.18 | 2025 | Contrave |
| Preventice Services, LLC | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Masci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.